Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004–2009

Highlights ► We present our experience as a provider consult service for individual AEFI. ► We assessed causality between the event and vaccine using modified WHO criteria. ► Consulting providers found the service to be useful. ► The CCCR provides a beneficial service to the U.S. vaccine safety infr...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-09, Vol.29 (40), p.6920-6927
Main Authors: Williams, S. Elizabeth, Klein, Nicola P, Halsey, Neal, Dekker, Cornelia L, Baxter, Roger P, Marchant, Colin D, LaRussa, Philip S, Sparks, Robert C, Tokars, Jerome I, Pahud, Barbara A, Aukes, Laurie, Jakob, Kathleen, Coronel, Silvia, Choi, Howard, Slade, Barbara A, Edwards, Kathryn M
Format: Article
Language:English
Subjects:
Adverse Drug Reaction Reporting Systems
Adverse event following immunization
Allergy and Immunology
Applied microbiology
Asthma
Bell's palsy
Biological and medical sciences
Case-Control Studies
Causality
Chronic fatigue syndrome
Data Collection - methods
Encephalitis
Family medical history
Fundamental and applied biological sciences. Psychology
Health care
human resources
Humans
Immunization
Immunization - adverse effects
Meningitis
Microbiology
physicians
Public health
Referral and Consultation
safety assessment
Studies
surveys
vaccination
Vaccines
Vaccines - adverse effects
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viruses
World Health Organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► We present our experience as a provider consult service for individual AEFI. ► We assessed causality between the event and vaccine using modified WHO criteria. ► Consulting providers found the service to be useful. ► The CCCR provides a beneficial service to the U.S. vaccine safety infrastructure.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.07.044